Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (FAKHRAVAC®) in healthy adults aged 18–55 years: Randomized, double-blind, placebo-controlled, phase I clinical trial

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (FAKHRAVAC®) in healthy adults aged 18–55 years: Randomized, double-blind, placebo-controlled, phase I clinical trial

Background: The FAKHRAVAC®, an inactivated SARS-CoV-2 vaccine, was assessed for safety and immunogenicity. Methods and findings: In this double-blind, placebo-controlled, phase I trial, we randomly assigned 135 healthy adults between 18 and 55 to receive vaccine strengths of 5 or 10 μg/dose or place...

Full description

Bibliographic Details
Main Authors: Akram Ansarifar, Ramin Hamidi Farahani, Ahmad Karimi Rahjerdi, Mohammadreza Ahi, Ali Sheidaei, Kimiya Gohari, Zahra Rahimi, Fatemeh Gholami, Pouria Basiri, Milad Moradi, Arash Jahangiri, Kosar Naderi, Soheil Ghasemi, Pezhman Khatami, Mohsen Honari, Samane Khodaverdloo, Mohammad Shooshtari, Hajar Mehr Azin, Sohrab Moradi, Batool Shafaghi, Hossein Allahyari, Arina Monazah, Ali Khodaei Poor, Hooman Bakhshande, Zahra Taghva, Mohammad Karimi Nia, Masoud Solaymani Dodaran, Mohsen Foroughizadeh
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:Vaccine: X
Subjects:
Clinical trial
Safety
Phase I
Inactivated vaccine
Immunogenicity
Online Access:http://www.sciencedirect.com/science/article/pii/S2590136223001420

Internet

http://www.sciencedirect.com/science/article/pii/S2590136223001420

Similar Items